News Category
Onco-Innovations has signed a non-binding LOI to potentially acquire exclusive rights to Ifowonco's oral small-molecule LAG-3 inhibitor program, which...
Creative Biolabs has expanded its complement assay services, offering specialized assays like C3b deposition and hemolytic inhibition to support the d...
Quantum BioPharma's Lucid-MS offers a novel approach to treating multiple sclerosis by targeting myelin degradation and smoldering lesions, potentiall...
Silo Pharma's receipt of a Canadian patent allowance for its lead PTSD drug candidate SPC-15 strengthens its global intellectual property position and...
Quantum BioPharma's Lucid-MS, a novel myelin-protecting therapy for multiple sclerosis, has received FDA clearance for phase 2 trials, potentially shi...
Regentis Biomaterials strengthens its intellectual property and manufacturing capabilities for GelrinC, advancing its commercialization efforts in Eur...
VERAXA Biotech's collaboration with AI firm Ardigen aims to use artificial intelligence to optimize its oncology pipeline, potentially reducing develo...
VERAXA Biotech's collaboration with AI firm Ardigen aims to enhance its oncology pipeline by using artificial intelligence to identify optimal dual-ta...
The American Heart Association is seeking market-ready digital health solutions for cardiovascular and brain care, with finalists pitching at Scientif...
Scientists have identified a protein on glioblastoma cells that could be targeted to make the cancer more vulnerable to existing treatments, potential...
NanoViricides has received regulatory approval to begin a Phase II trial of its oral antiviral NV-387 for Ebola in the Democratic Republic of Congo, p...
Helus Pharma appoints Regina Donohue as Chief People Officer and Dr. Suresh Durgam to its Scientific Advisory Board, strengthening its organizational ...
The 20th Annual Sickle Cell Disease Educational Summit, hosted by Cayenne Wellness Center, commemorates two decades of progress in sickle cell care wh...
Helix BioPharma has appointed Dr. Markus Loeffler as Chief Medical Officer to lead the clinical development of L-DOS47 and LEUMUNA, marking a strategi...
Quantum BioPharma reported significant expense reductions and FDA approval for its Phase 2 trial of Lucid-MS, a potential treatment for progressive mu...
Regentis Biomaterials is simultaneously progressing its GelrinC cartilage repair implant through a pivotal U.S. trial and European commercialization, ...
Alpha Cognition's Q2 2026 results show a 71% quarter-over-quarter revenue increase for ZUNVEYL, driven by organic demand and deeper adoption despite l...
The Lung Cancer Foundation of America and the International Association for the Study of Lung Cancer are investing $400,000 in two promising early-car...
PX1 Research's domestically manufactured research peptides now pass a rigorous seven-stage testing protocol, ensuring 99%+ purity and batch-level trac...
A comprehensive review provides a structured approach to surgical management of necrotizing enterocolitis in premature infants, emphasizing bowel pres...
Onco-Innovations is building the scientific foundation for its precision oncology drug ONC010, a nanoparticle-encapsulated PNKP inhibitor, through man...
Regentis Biomaterials' GelrinC, a cell-free hydrogel implant, gains European approval for a scalable manufacturing process and progresses U.S. trials,...
Researchers at the University of Manchester discovered that a subset of immune cells, previously overlooked, plays a crucial role in orchestrating and...
Quantum BioPharma reported a 53% reduction in operating expenses and received FDA approval for its Phase 2 trial of Lucid-MS, a potential treatment fo...
Regentis Biomaterials accelerates GelrinC's path to market by simultaneously progressing US Phase III trials and European commercialization, potential...
Lantern Pharma's Q2 2026 results show significant pipeline progress and strategic moves, including the establishment of Open Medicine AI as a separate...
Helus Pharma's Phase 3 program for HLP003 in major depressive disorder is on track with enrollment completed in the first pivotal study, positioning t...
DM Clinical Research celebrates its 20th anniversary, highlighting its growth into a leading clinical research network with over 35 sites and 35,000 p...
NeOnc Technologies' NEO100 met its primary endpoint in a Phase 2a trial for recurrent brain cancer, showing significant survival benefits and tolerabi...
PX1 Research's new batches of retatrutide and tirzepatide peptides, manufactured under cGMP and verified by HPLC, meet high purity standards, supporti...
Quantum BioPharma is developing Lucid-MS, a therapy aimed at inhibiting myelin degradation and preserving myelin, to address progression independent o...
GeoVax offers its MVA-based hemorrhagic fever vaccine expertise and candidates to aid the global response to the fast-growing Bundibugyo Ebola outbrea...
Amidst looming tariffs on drug imports, global pharmaceutical companies are investing approximately $500 billion in US operations, a move that could r...
Nutriband CEO Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit, underscoring the company's commitment to advancing its AVERSA abu...
Quantum BioPharma's FDA approval to initiate Phase 2 trials for Lucid-MS, a novel neuroprotective candidate targeting myelin repair, marks a pivotal s...
PX1 Research launches US-manufactured sublingual peptide strips, including retatrutide, for needle-free research applications, emphasizing cGMP compli...
PX1 Research now applies seven-stage HPLC purity verification and cGMP quality control to its US-manufactured research peptides, offering batch-specif...
NanoViricides has received approval to begin a Phase II trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more accessibl...
New research from the University of Virginia suggests focused ultrasound could make brain cancer treatments more effective and less harmful, potential...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn suppresses tumor growth in TNBC models, supporting its Phase 1/2 t...
Quantum BioPharma's IND approval for Lucid-MS enables Phase 2 testing, potentially offering a novel neuroprotective approach to MS by targeting demyel...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, driven by TONMYA's commercial success, positioning the company for continued growth an...
Tonix Pharmaceuticals' second-quarter 2026 results show a significant revenue jump driven by TONMYA, the first new fibromyalgia treatment in over 15 y...
Tonix Pharmaceuticals' Q2 2026 revenue surged to $13.5 million, driven by TONMYA's $11 million in sales, signaling strong commercial uptake and pipeli...
A new narrative review in the World Journal of Pediatric Surgery provides a comprehensive framework for risk-adapted neuroblastoma care, emphasizing t...
Regentis Biomaterials is progressing its GelrinC cartilage regeneration technology through clinical trials, FDA submission preparation, European comme...
Quantum BioPharma advances its two-pronged approach to neurological health, with Lucid-MS targeting myelin repair in multiple sclerosis and unbuzzd ad...
Quantum BioPharma is progressing two initiatives for neurological health: its investigational MS therapy Lucid-MS, which has an FDA IND submission for...
